GENinCodeLSE:GENI -3.23% Days Payable is 463.81 as of Dec. 2025, which is 75% above its 10-year median of 264.84. The stock has 4 warning signs investors should review. Among 191 Medical Diagnostics & Research companies, GENinCode ranks better than 88.48% on this metric.
GENinCode's average Accounts Payable for the
six
months ended in Dec. 2025 was £1.32 Mil. GENinCode's Cost of Goods Sold for the
six
months ended in Dec. 2025 was £0.52 Mil.
Hence, GENinCode's Days Payable for the
six
months ended in Dec. 2025 was 463.81.
The historical rank and industry rank for GENinCode's Days Payable or its related term are showing as below:
LSE:GENI'
s Days Payable Range Over the Past 10 Years
Min: 175.02 Med: 264.84 Max: 418.56
Current: 310.86
During the past 7 years, GENinCode's highest Days Payable was 418.56. The lowest was 175.02. And the median was 264.84.
LSE:GENI's Days Payable is ranked better than 88.48% of 191
companies
in the Medical Diagnostics & Research industry
Industry Median: 65.09
vs LSE:GENI: 310.86
GENinCode's Days Payable
increased
from Dec. 2024 (294.78) to Dec. 2025 (463.81).
It may suggest that GENinCodedelayed paying its suppliers.
GENinCode Days Payable Related Terms
GENinCode Days Payable Historical Data
* Premium members only.
The historical data trend for GENinCode's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:GENI vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, GENinCode's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GENinCode Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, GENinCode's Days Payable distribution charts can be found below:
* The bar in red indicates where GENinCode's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
GENinCode's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GENinCode (LSE:GENI) has a Days Payable of 463.81 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on GENinCode and its competitors. This is 75% above median its historical median of 264.84. Over the past decade, GENinCode's Days Payable has ranged from 175.02 to 418.56. According to the industry distribution chart, GENinCode ranks #22 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 11.5%.
Is GENinCode's Days Payable too high?
GENinCode's current Days Payable of 463.81 is 75% above median its 10-year median of 264.84. Over the past 10 years, this metric has ranged from a low of 175.02 to a high of 418.56. The Medical Diagnostics & Research industry median Days Payable is 65.09. GENinCode's value of 463.81 is 612.6% above this industry median. Based on the distribution chart, GENinCode ranks #22 out of 191 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does GENinCode's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, GENinCode ranks #22 out of 191 companies for Days Payable. This places GENinCode in the top 12% of its industry — outperforming the majority of peers. The industry median Days Payable is 65.09. GENinCode's value of 463.81 is 612.6% above this benchmark. Historically, GENinCode's own Days Payable has ranged from 175.02 to 418.56 over the past decade. While the company's 10-year median is 264.84 vs. the industry median of 65.09, GENinCode has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 65.09, based on 191 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GENinCode's current Days Payable of 463.81 is 612.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on GENinCode and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 65.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GENinCode's current Days Payable is 463.81, which is 75% above median its own 10-year median of 264.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GENinCode stock overvalued right now?
Based on GuruFocus' analysis, GENinCode (LSE:GENI) is currently considered Possible Value Trap. The stock's GF Value™ is £0.04, compared to a current price of £0.01 — trading 77.5% below its estimated fair value. The current Days Payable is 463.81, which is 75% above median its 10-year median of 264.84 and 612.6% above the Medical Diagnostics & Research industry median of 65.09. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For GENinCode (LSE:GENI), the current Days Payable is 463.81 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
GENinCode PLC principal activity is the development and commercialisation of clinical genetic tests, to provide predictive analysis of risk to a patient's health based on their genes. The company has one operating segment. The company has presence in Spain, UK, United States, Italy, Germany, and Rest of World. The company generates majority of revenue from Spain. Its commercial products are CE-Marked, with CARDIO inCode, THROMBO inCode, and LIPID inCode.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:GENI has been successfully added to your 